

# Stefan Kasper

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5242553/publications.pdf>

Version: 2024-02-01

122  
papers

9,052  
citations

136950

32  
h-index

42399

92  
g-index

132  
all docs

132  
docs citations

132  
times ranked

12782  
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141. <i>Oncologist</i> , 2022, 27, e194-e198.	3.7	18
2	Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (<scp>LICC</scp>, <scp>CELIM</scp>, <scp>FIRE</scp>â€³). <i>International Journal of Cancer</i> , 2022, 150, 1341-1349.	5.1	6
3	Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP. <i>British Journal of Cancer</i> , 2021, 124, 721-727.	6.4	5
4	Combined systemic inflammation score (SIS) correlates with prognosis in patients with advanced pancreatic cancer receiving palliative chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 579-591.	2.5	17
5	Changes in fatigue, barriers, and predictors towards physical activity in advanced cancer patients over a period of 12 monthsâ€”a comparative study. <i>Supportive Care in Cancer</i> , 2021, 29, 5127-5137.	2.2	3
6	Noninferiority of cetuximab every-2-weeks versus standard once-weekly administration schedule for the first-line treatment of RAS wild-type metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2021, 144, 291-301.	2.8	8
7	GPR15 Facilitates Recruitment of Regulatory T Cells to Promote Colorectal Cancer. <i>Cancer Research</i> , 2021, 81, 2970-2982.	0.9	17
8	Dose-escalated radiotherapy with PET/CT based treatment planning in combination with induction and concurrent chemotherapy in locally advanced (uT3/T4) squamous cell cancer of the esophagus: mature results of a phase I/II trial. <i>Radiation Oncology</i> , 2021, 16, 59.	2.7	4
9	Identification of a Prognostic Clinical Score for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Systemic Therapy Including Cetuximab. <i>Frontiers in Oncology</i> , 2021, 11, 635096.	2.8	3
10	Antitumor immune response is associated with favorable survival in GEP-NEN G3. <i>Endocrine-Related Cancer</i> , 2021, 28, 683-693.	3.1	2
11	Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC). <i>Oncoimmunology</i> , 2020, 9, 1806680.	4.6	11
12	Mapping Patient Data to Colorectal Cancer Clinical Algorithms for Personalized Guideline-Based Treatment. <i>Applied Clinical Informatics</i> , 2020, 11, 200-209.	1.7	7
13	A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment. <i>Investigational New Drugs</i> , 2020, 38, 1774-1783.	2.6	13
14	Fatigue, barriers to physical activity and predictors for motivation to exercise in advanced Cancer patients. <i>BMC Palliative Care</i> , 2020, 19, 43.	1.8	54
15	Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX Trial. <i>Clinical Colorectal Cancer</i> , 2020, 19, 236-247.e6.	2.3	5
16	Photochemical internalization and gemcitabine combined with first-line chemotherapy in perihilar cholangiocarcinoma: observations in three patients. <i>Endoscopy International Open</i> , 2020, 08, E1878-E1883.	1.8	7
17	Nivolumab treatment beyond RECISTâ€”defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial. <i>Cancer</i> , 2019, 125, 3208-3218.	4.1	64
18	A biomarker combination indicating resistance to FOLFOX plus bevacizumab in metastatic colorectal cancer: Results of phase I of the PERMAD trial. <i>Annals of Oncology</i> , 2019, 30, v219-v220.	1.2	1

#	ARTICLE	IF	CITATIONS
19	Noninferiority on overall survival of every-2-weeks vs weekly schedule of cetuximab for first-line treatment of RAS wild-type metastatic colorectal cancer. <i>Annals of Oncology</i> , 2019, 30, v220-v221.	1.2	2
20	Post-hoc analyses of a subgroup of patients with advanced biliary tract cancer (BTC) who crossed over to treatment with etoposide toniribate (EDO-S7.1) in a randomized phase II study. <i>Annals of Oncology</i> , 2019, 30, v278.	1.2	2
21	The IL-33/ST2 pathway shapes the regulatory T cell phenotype to promote intestinal cancer. <i>Mucosal Immunology</i> , 2019, 12, 990-1003.	6.0	107
22	Natural language processing of German clinical colorectal cancer notes for guideline-based treatment evaluation. <i>International Journal of Medical Informatics</i> , 2019, 127, 141-146.	3.3	19
23	Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. <i>Lancet, The</i> , 2019, 393, 1948-1957.	13.7	1,494
24	Impact of RAS mutation subtype on clinical outcome—a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer. <i>Oncogene</i> , 2019, 38, 2953-2966.	5.9	38
25	Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocols. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 445-455.	2.5	6
26	Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2507-2507.	1.6	113
27	PET-directed combined modality therapy for gastroesophageal junction cancer: First results of the prospective MEMORI trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4018-4018.	1.6	6
28	Paclitaxel/carboplatin with or without cetuximab for treatment of carcinoma with unknown primary (PACET-CUP): Results of a multi-center randomized phase II AIO trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4120-4120.	1.6	2
29	A phase IIb study of ramucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic, chemotherapy refractory colorectal cancer patients: The RAMTAS trial of the German AIO (KRK-0316).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS3617-TPS3617.	1.6	1
30	Survival after secondary liver resection in metastatic colorectal cancer: A comparative analysis of the LICC trial with historical controls (CELIM, FIRE-3).. <i>Journal of Clinical Oncology</i> , 2019, 37, 571-571.	1.6	1
31	Long-term Survival after resection for perihilar cholangiocarcinoma: Impact of UICC staging and surgical procedure. <i>Turkish Journal of Gastroenterology</i> , 2019, 30, 454-460.	1.1	11
32	Randomized phase II trial of the carboxylesterase (CES)-converted novel drug EDO-S7.1 in patients (pts) with advanced biliary tract cancers (BTC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 264-264.	1.6	0
33	A randomized, double-blinded, placebo-controlled multicenter phase II trial of adjuvant immunotherapy with tecemotide (L-BLP25) after R0/R1 hepatic colorectal cancer metastasectomy (LICC): Final results.. <i>Journal of Clinical Oncology</i> , 2019, 37, 480-480.	1.6	0
34	Survival after primary liver resection in metastatic colorectal cancer: A comparative analysis of the LICC trial with historical controls (FFCD ACHBTH AURC 9002 trial and EORTC Intergroup trial 40983).. <i>Journal of Clinical Oncology</i> , 2019, 37, e15019-e15019.	1.6	0
35	A randomized, double-blinded, placebo-controlled multicenter phase II trial of adjuvant immunotherapy with tecemotide (L-BLP25) after R0/R1 hepatic colorectal cancer metastasectomy (LICC): Final results.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3537-3537.	1.6	0
36	Survival after secondary liver resection in metastatic colorectal cancer: A comparative analysis of the LICC trial with historical controls (CELIM, FIRE-3).. <i>Journal of Clinical Oncology</i> , 2019, 37, e15025-e15025.	1.6	0

#	ARTICLE	IF	CITATIONS
37	Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. <i>Oral Oncology</i> , 2018, 81, 45-51.	1.5	589
38	PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer—a randomised biomarker-driven clinical phase II AIO study. <i>European Journal of Cancer</i> , 2018, 92, 11-19.	2.8	55
39	Two-year Update From CheckMate 141: Outcomes With Nivolumab (Nivo) vs Investigator's Choice (IC) in Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the Overall Population and PD-L1 Subgroups. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1317.	0.8	11
40	MET Expression in Advanced Non-Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy. <i>Clinical Lung Cancer</i> , 2018, 19, e441-e463.	2.6	61
41	Phosphorylation of p70 Ribosomal Protein S6 Kinase $\beta$ -1 is an Independent Prognostic Parameter in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, e331-e352.	2.3	13
42	PhotoChemical internalization of gemcitabine followed by gemcitabine/cisplatin in perihilar cholangiocarcinoma: Results from a phase I dose escalation trial. <i>Annals of Oncology</i> , 2018, 29, viii259-viii260.	1.2	0
43	A novel biomarker combination and its association with resistance to chemotherapy combinations with bevacizumab: First results of the PERMAD trial. <i>Annals of Oncology</i> , 2018, 29, viii159.	1.2	0
44	Safety profile of trifluridine/tipiracil monotherapy in clinical practice: results of the German compassionate-use program for patients with metastatic colorectal cancer. <i>BMC Cancer</i> , 2018, 18, 1124.	2.6	13
45	Comparison of the sixth and the seventh editions of the UICC classification for intrahepatic cholangiocarcinoma. <i>European Journal of Medical Research</i> , 2018, 23, 29.	2.2	2
46	CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. <i>Oncologist</i> , 2018, 23, 1079-1082.	3.7	70
47	Kopf-Hals-Tumoren beim alten und geriatrischen Patienten. , 2018, , 299-309.		0
48	A novel biomarker combination and its association with resistance to chemotherapy combinations with bevacizumab: First results of the PERMAD trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15545-e15545.	1.6	0
49	Abstract CT116: Nivolumab (Nivo) vs investigator's choice (IC) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): 2-yr outcomes in the overall population and PD-L1 subgroups of CheckMate 141. <i>Cancer Research</i> , 2018, 78, CT116-CT116.	0.9	4
50	Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 323-335.	10.7	173
51	Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression. <i>Nature Communications</i> , 2017, 8, 14447.	12.8	22
52	Comprehensive Biomarker Analyses in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer Prospectively Treated with the Polo-Like Kinase 1 Inhibitor BI2536. <i>Oncology Research and Treatment</i> , 2017, 40, 435-439.	1.2	7
53	Phase I clinical study with photochemical internalisation, a novel technology for treatment of perihilar cholangiocarcinoma. <i>Journal of Hepatology</i> , 2017, 66, S452.	3.7	1
54	Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1104-1115.	10.7	325

#	ARTICLE	IF	CITATIONS
55	High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 54-64.	1.1	62
56	Treatment beyond progression with nivolumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the phase 3 checkmate 141 study: A biomarker analysis and updated clinical outcomes. <i>Annals of Oncology</i> , 2017, 28, v372-v373.	1.2	35
57	Nivolumab vs investigator's choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): treatment effect on clinical outcomes by best overall response in checkmate 141. <i>Annals of Oncology</i> , 2017, 28, v377-v378.	1.2	1
58	Abstract CT021: Tumor-associated immune cell PD-L1 expression and peripheral immune profiling: Analyses from CheckMate 141. <i>Cancer Research</i> , 2017, 77, CT021-CT021.	0.9	13
59	Abstract CT157: Treatment beyond progression with nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck in the phase 3 Checkmate 141 study. , 2017, , .		6
60	Nivolumab (Nivo) vs investigator's choice (IC) for platinum-refractory (PR) recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN; Checkmate 141): Outcomes in first-line (1L) R/m patients and updated safety and efficacy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6019-6019.	1.6	20
61	Characterization of potential predictive biomarkers of response to nivolumab in CheckMate 141 in patients with squamous cell carcinoma of the head and neck (SCCHN).. <i>Journal of Clinical Oncology</i> , 2017, 35, 6050-6050.	1.6	7
62	Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy. <i>Oncotarget</i> , 2017, 8, 45898-45917.	1.8	12
63	Kopf-Hals-Tumoren beim alten und geriatrischen Patienten. , 2017, , 1-11.		0
64	Characterization of potential predictive biomarkers of response to nivolumab in CheckMate-141 in patients with squamous cell carcinoma of the head and neck (SCCHN).. <i>Journal of Clinical Oncology</i> , 2017, 35, 5-5.	1.6	1
65	Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. <i>New England Journal of Medicine</i> , 2016, 375, 1856-1867.	27.0	3,845
66	Randomized phase II study of maintenance treatment with 5-FU/FA plus panitumumab vs 5-FU/FA alone after induction (mFOLFOX6 plus panitumumab) in patients with RAS WT metastatic colorectal cancer. <i>Annals of Oncology</i> , 2016, 27, vi205.	1.2	1
67	Cetuximab biweekly (q2w) plus mFOLFOX6 as 1st line therapy in patients (pts) with KRAS wild-type (wt) (exon 2) metastatic colorectal cancer (mCRC) – Primary endpoint and subgroup analysis of the CEBIFOX trial. <i>Annals of Oncology</i> , 2016, 27, vi167.	1.2	1
68	Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 795-805.	2.5	34
69	Abstract CT099: Nivolumab (nivo) vs investigator's choice (IC) for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): CheckMate-141. <i>Cancer Research</i> , 2016, 76, CT099-CT099.	0.9	18
70	Further evaluations of nivolumab (nivo) versus investigator's choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6009-6009.	1.6	32
71	Differences in gene-expression in mCRC tissue samples with regard to tumor location and used chemotherapeutic substances: Data of the FIRE-1 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 562-562.	1.6	0
72	Randomized, multicenter phase II trial of CAP7.1 in patients with advanced biliary tract cancers.. <i>Journal of Clinical Oncology</i> , 2016, 34, 441-441.	1.6	0

#	ARTICLE	IF	CITATIONS
73	Population pharmacokinetics of CAP7.1 and the effect on total target lesion size in adult patients with biliary tract cancer.. Journal of Clinical Oncology, 2016, 34, e15602-e15602.	1.6	0
74	P1310 : Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1) â€“ a randomized, multidisciplinary, multinational phase III trial. Journal of Hepatology, 2015, 62, S845.	3.7	0
75	HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomas. Lung Cancer, 2015, 88, 34-41.	2.0	17
76	Panitumumab in combination with gemcitabine/cisplatin (GemCis) for patients with advanced kRAS WT biliary tract cancer: A randomized phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).. Journal of Clinical Oncology, 2015, 33, 4082-4082.	1.6	8
77	Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1): A randomized, multidisciplinary, multinational phase III trial.. Journal of Clinical Oncology, 2015, 33, TPS4140-TPS4140.	1.6	1
78	Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) (exon) Tj ETQq0 0 0 rgBT /Overlock 1 Journal of Clinical Oncology, 2015, 33, 3568-3568.	1.6	1
79	Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy. Cell Death and Disease, 2014, 5, e1091-e1091.	6.3	24
80	Functional expression cloning identifies COX-2 as a suppressor of antigen-specific cancer immunity. Cell Death and Disease, 2014, 5, e1568-e1568.	6.3	42
81	Targeted therapies in gastroesophageal cancer. European Journal of Cancer, 2014, 50, 1247-1258.	2.8	45
82	Transient Ablation of Regulatory T cells Improves Antitumor Immunity in Colitis-Associated Colon Cancer. Cancer Research, 2014, 74, 4258-4269.	0.9	84
83	Development of a Highly Sensitive and Specific Method for Detection of Circulating Tumor Cells Harboring Somatic Mutations in Non-Small-Cell Lung Cancer Patients. PLoS ONE, 2014, 9, e85350.	2.5	51
84	Current Status of Immunotherapy in Gastroesophageal Cancer. , 2014, , 179-191.		0
85	A randomized, double-blind, placebo-controlled, multicenter, binational, phase II trial of immunotherapy with L-BLP25 (tecemotide) in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy.. Journal of Clinical Oncology, 2014, 32, TPS3658-TPS3658.	1.6	0
86	Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patients. Breast Cancer Research and Treatment, 2013, 142, 81-88.	2.5	3
87	Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer Center. European Journal of Cancer, 2013, 49, 3076-3082.	2.8	26
88	Stabilization of Physical RAF/14-3-3 Interaction by Cotylenin A as Treatment Strategy for RAS Mutant Cancers. ACS Chemical Biology, 2013, 8, 1869-1875.	3.4	105
89	Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade. Oncogene, 2013, 32, 2873-2881.	5.9	32
90	A genome-wide RNAi screen identifies proteins modulating aberrant FLT3-ITD signaling. Leukemia, 2013, 27, 2301-2310.	7.2	8



#	ARTICLE	IF	CITATIONS
91	Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC): An interim analysis of the CEBIFOX trial.. Journal of Clinical Oncology, 2013, 31, e14502-e14502.	1.6	0
92	A randomized, double-blind, placebo-controlled, multicenter, multinational, phase II trial immunotherapy with L-BLP25 (tecemotide) in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy.. Journal of Clinical Oncology, 2013, 31, TPS3124-TPS3124.	1.6	0
93	Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies. Blood Cancer Journal, 2012, 2, e60-e60.	6.2	68
94	LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases—a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial. BMC Cancer, 2012, 12, 144.	2.6	16
95	β-tubulin expression is associated with outcome following taxane-based chemotherapy in non-small cell lung cancer. British Journal of Cancer, 2012, 107, 823-830.	6.4	33
96	Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2012, 138, 545-554.	2.5	6
97	Molecular dissection of effector mechanisms of RAS-induced resistance to monoclonal anti-EGFR antibodies.. Journal of Clinical Oncology, 2012, 30, 501-501.	1.6	1
98	A randomized, double-blind, placebo-controlled, multicenter, multinational, phase II trial of L-BLP25 in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy.. Journal of Clinical Oncology, 2012, 30, TPS3641-TPS3641.	1.6	0
99	Simultaneous protection against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR-signaling blockade by oncogenic RAS.. Journal of Clinical Oncology, 2011, 29, 440-440.	1.6	0
100	P4-07-05: Comparison of PIK3CA Hot Spot Mutations in the Primary Tumor or Metastases with PIK3CA Mutations or PIK3CA Over-Expression in Circulating Tumor Cells of Metastatic Breast Cancer Patients under Sequential Palliative Therapy.. , 2011, , .		0
101	A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML. Blood, 2009, 113, 4063-4073.	1.4	106
102	The kinase inhibitor LS104 induces apoptosis, enhances cytotoxic effects of chemotherapeutic drugs and is targeting the receptor tyrosine kinase FLT3 in acute myeloid leukemia. Leukemia Research, 2008, 32, 1698-1708.	0.8	24
103	LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells. Molecular Cancer Therapeutics, 2008, 7, 1176-1184.	4.1	44
104	Cross-Inhibition of Interferon-Induced Signals by GM-CSF Through a Block in Stat1 Activation. Journal of Interferon and Cytokine Research, 2007, 27, 947-960.	1.2	13
105	Protein A immunoadsorption therapy for refractory, mitomycin C-associated thrombotic microangiopathy. Transfusion, 2007, 47, 1263-1267.	1.6	14
106	The JAK2 Kinase Inhibitor LS104 Induces Growth-Arrest and Apoptosis in JAK2V617F Positive Cells.. Blood, 2007, 110, 3544-3544.	1.4	1
107	Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood, 2006, 107, 293-300.	1.4	252
108	Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML). Blood, 2005, 105, 335-340.	1.4	97

#	ARTICLE	IF	CITATIONS
109	In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C. <i>Leukemia</i> , 2003, 17, 999-1009.	7.2	36
110	Serotonin-selektive Antidepressiva(SSRI, DSA). , 2002, , 223-363.		0
111	Topiramate as a mood stabilizer. <i>International Clinical Psychopharmacology</i> , 2001, 16, 295-298.	1.7	12
112	Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. <i>International Clinical Psychopharmacology</i> , 2001, 16, 75-86.	1.7	147
113	A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer's disease. <i>International Clinical Psychopharmacology</i> , 2001, 16, 253-263.	1.7	54
114	Predictors of response to pharmacotherapy with citalopram in obsessive-compulsive disorder. <i>International Clinical Psychopharmacology</i> , 2001, 16, 357-361.	1.7	52
115	Effective open-label treatment of Tourette's disorder with olanzapine. <i>International Clinical Psychopharmacology</i> , 2000, 15, 23-28.	1.7	61
116	P01.104 Relation of suicidal behaviour, central serotonergic system and temperament and character inventory. <i>European Psychiatry</i> , 2000, 15, 347s-348s.	0.2	0
117	P.6.078 Personality traits in affective disorders as hints to biological disturbances. <i>European Neuropsychopharmacology</i> , 1997, 7, S288.	0.7	2
118	P.6.079 Risperidone in Gilles de la Tourette syndrome patients unresponsive to typical neuroleptics. <i>European Neuropsychopharmacology</i> , 1997, 7, S288.	0.7	0
119	P.6.083 Enhanced striatal dopamine transporter activity in drug naive and previously treated patients with Gilles de la Tourette syndrome (GTS): A [ <sup>123</sup> I]-β-CIT SPECT-study. <i>European Neuropsychopharmacology</i> , 1997, 7, S289-S290.	0.7	0
120	Risperidone in the treatment of Gilles de la Tourette Syndrome. <i>European Neuropsychopharmacology</i> , 1996, 6, S4-163.	0.7	0
121	Risperidone for Tourette's syndrome. <i>Lancet</i> , The, 1994, 344, 1577-1578.	13.7	43
122	ARTHROPATHIES AND SCHIZOPHRENIA. <i>Lancet</i> , The, 1980, 316, 536-537.	13.7	7